Tough Time Wisdom
A conversation with Charles Hsu, Ph.D., Bay City Capital - Part II
65 views
00:12:26 - Uploaded by Song Essinova, LLC on February 20, 2009
In this segment, Charles Hsu expresses his views on the global financial crisis - its short term vs. long term impact, absolute vs. relative opportunities for investments, and potential positive effects of a down market.
Mr. Hsu is a Venture Partner at Bay City Capital. He has over 25 years of experience in the life sciences industry, most of which as an entrepreneur and venture capitalist focusing on early-stage life science and health care firms. He has co-founded or invested in over 25 companies, and has served on 15 boards of directors, including Axys Pharmaceuticals, KOSAN, Lexicon Genetics, Biomatrix and Aviron., all of which went public on NASDAQ. Mr. Hsu is active internationally, having worked with several companies in Europe, Israel and Asia. He was a co-founding investor in Asia Renal Care, which became Asia's largest and most profitable independent kidney dialysis provider. He has been a founder, investor, director or advisor with several companies in the Greater China region including Wuxi Pharmatech, Eureka, Progentech and LEAD Therapeutics. Mr. Hsu received his PhD in Genetics and MBA from Stanford University, and an AB degree (Magna cum Laude) in Biochemistry from Harvard. He is frequently invited to speak at conferences and has published articles on the life science opportunities in Asia.
Tags: Charles Hsu, Bay City Capital, China biotech, financial crisis
COMMENTS
There are 0 comments. You must be logged in to comment.
Opinions & Expertise
-
Changing the FDA Approval Process
-
Innovating Health Sciences to Reduce Cost
-
Entering the Health Age
-
China's Healthcare Reform
-
The Big Reboot Is Yet to Come - from Mindboggling Science
-
The Synthetic Biology Debate - The Voice for It
-
The Synthetic Biology Debate - The Voice Against It
-
China - Half Way Up the Value Chain, and Growing Rapidly
-
Tough Time Wisdom
-
The System Is Not Optimal!
